The Trump administration disbanded a federal newborn screening panel. Advocates now face a harder pathnews2025-07-15T13:30:58+00:00July 15th, 2025|Endpoints News|
US investors divided on China’s biotech risenews2025-07-02T15:00:45+00:00July 2nd, 2025|Endpoints News|
Advocates urge J&J to ‘put everything on the table’ for gene therapy despite failed trialnews2025-07-01T14:48:52+00:00July 1st, 2025|Endpoints News|
A custom ALS drug could help scale rare disease therapiesnews2025-06-18T15:00:06+00:00June 18th, 2025|Endpoints News|
With HIV prevention under attack, how might Gilead’s new PrEP injection fare?news2025-06-13T14:30:31+00:00June 13th, 2025|Endpoints News|
Reality check: Unpacking the $150B GLP-1 market forecastsnews2025-06-11T14:00:23+00:00June 11th, 2025|Endpoints News|
Rebooting dead human brains, biotech seeks to reinvent drug testing worknews2025-06-10T14:00:49+00:00June 10th, 2025|Endpoints News|
Struggling biotechs succumb to icy market, as money dries up and clinical bets don’t pay offnews2025-06-04T14:00:32+00:00June 4th, 2025|Endpoints News|
How Illumina’s ex-employees became its customers and competitorsnews2025-05-29T13:00:07+00:00May 29th, 2025|Endpoints News|
A new dawn for psychedelics? Compass could be the first to find outnews2025-05-28T14:00:03+00:00May 28th, 2025|Endpoints News|
